Leigh Anne Siino on The Spherix Global’s Translation of ASH25 Insights Into Actionable Intelligence
Leigh Anne Siino, Chief Revenue Officer at Spherix Global Insights, shared on LinkedIn:
”The Spherix Global Insights Hematology/Oncology team is translating key insights from ASH25 into actionable intelligence — helping strategy, commercial, and medical teams across pharma prepare for the next wave of change across benign and malignant hematology.
What we’re seeing and why it matters now:
Sickle Cell Disease: Turning Patient Voice and Data Into Advantage
SCD is entering a pivotal period, with growing emphasis on coordinated patient-level data and deeper incorporation of patient perspectives.
As pipelines advance and treatment options expand, organizations with timely, centralized insights will be best positioned to optimize targeting, prepare for launches, and align strategies with real-world care delivery.
Cross-Therapeutic Mechanisms and Gene Therapy in Benign Hematology
ASH underscored rising interest in therapies with shared mechanisms across conditions — including autoimmune cytopenias, SCD, hemophilia, and vWD — alongside continued focus on gene therapies.
These dynamics reinforce the need for cross-therapy intelligence to support faster, evidence-based decision-making as indications evolve.
Malignant Hematology: Next-Gen Modalities and Earlier-Line Opportunity
In malignant disease, advances in CAR-T platforms, expanding AML pipelines, and movement into earlier lines (including smoldering multiple myeloma) are reshaping both clinical and commercial landscapes.
Explore our latest and upcoming hematology publications on the Spherix Client Portal.”
All from ASH25 featured in Hemostasis Today.
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV